drugset / Trial / NCT05014776
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Phase 2
Completed
17 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lustgarten Foundation · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and clinical activity of tadalafil, pembrolizumab, ipilimumab, and CRS-207 in subjects with metastatic pancreatic adenocarcinoma who have progressed after at least 1 prior chemotherapy regimen.
Timeline
- Start
- 2022-08-22
- Primary completion
- 2024-04-03
- Completion
- 2025-06-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CRS-207 | Vaccine | 1e+09 unknown | Intravenous |
| Subject | Ipilimumab | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tadalafil | Small molecule | 20 mg | Oral |